Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

医学 耐受性 免疫原性 不利影响 接种疫苗 病毒学 内科学 免疫学 抗体 安慰剂 随机对照试验 血清转化 重组DNA
作者
Fengcai Zhu,Yuhua Li,Xuhua Guan,Lihua Hou,Wenjuan Wang,Jingxin Li,Shipo Wu,Busen Wang,Xiaolong Yang,Lei Wang,Siyue Jia,Hu-Dachuan Jiang,Ling Wang,Tao Jiang,Yi Hu,Jin-Bo Gou,Shabei Xu,Hong Shang,Xuewen Wang,Wei Wang,Wei Chen
出处
期刊:The Lancet [Elsevier BV]
卷期号:395 (10240): 1845-1854 被引量:956
标识
DOI:10.1016/s0140-6736(20)31208-3
摘要

A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain.We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrolled and allocated to one of three dose groups (5 × 1010, 1 × 1011, and 1·5 × 1011 viral particles) to receive an intramuscular injection of vaccine. The primary outcome was adverse events in the 7 days post-vaccination. Safety was assessed over 28 days post-vaccination. Specific antibodies were measured with ELISA, and the neutralising antibody responses induced by vaccination were detected with SARS-CoV-2 virus neutralisation and pseudovirus neutralisation tests. T-cell responses were assessed by enzyme-linked immunospot and flow-cytometry assays. This study is registered with ClinicalTrials.gov, NCT04313127.Between March 16 and March 27, 2020, we screened 195 individuals for eligibility. Of them, 108 participants (51% male, 49% female; mean age 36·3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. All enrolled participants were included in the analysis. At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83%) participants in the low dose group, 30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination.The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation.National Key R&D Program of China, National Science and Technology Major Project, and CanSino Biologics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
666完成签到,获得积分10
刚刚
英勇的沛春完成签到 ,获得积分10
1秒前
Roach完成签到,获得积分10
1秒前
好哥哥会更好完成签到,获得积分10
1秒前
1秒前
Lion Li发布了新的文献求助200
2秒前
阿容完成签到,获得积分10
2秒前
陈陈陈完成签到 ,获得积分20
2秒前
生椰拿铁完成签到 ,获得积分10
3秒前
666发布了新的文献求助10
4秒前
标致博完成签到,获得积分10
5秒前
fs完成签到,获得积分10
5秒前
Tia完成签到 ,获得积分10
6秒前
安澜应助张111采纳,获得10
7秒前
8秒前
8秒前
fs发布了新的文献求助10
9秒前
沉默的灵寒完成签到,获得积分10
10秒前
yzxzdm完成签到 ,获得积分10
10秒前
11秒前
12秒前
嘻嘻完成签到,获得积分10
12秒前
纪贝贝完成签到,获得积分10
13秒前
13秒前
13秒前
从容芮应助Fairy采纳,获得30
14秒前
任老师发布了新的文献求助10
14秒前
15秒前
罗小小发布了新的文献求助10
16秒前
1142722完成签到,获得积分10
16秒前
十八完成签到 ,获得积分10
17秒前
大个应助杨小么采纳,获得10
17秒前
mescal完成签到,获得积分10
17秒前
皮皮的鹿完成签到,获得积分10
17秒前
科研小崽发布了新的文献求助10
18秒前
st完成签到,获得积分10
18秒前
18秒前
kk完成签到,获得积分10
18秒前
qhdsyxy完成签到 ,获得积分0
18秒前
19秒前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
Indomethacinのヒトにおける経皮吸収 400
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 370
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3991212
求助须知:如何正确求助?哪些是违规求助? 3532463
关于积分的说明 11257687
捐赠科研通 3271490
什么是DOI,文献DOI怎么找? 1805436
邀请新用户注册赠送积分活动 882386
科研通“疑难数据库(出版商)”最低求助积分说明 809312